Gliptinaid M 1000 Tablet ER is a combination oral antidiabetic medication containing Metformin 1000 mg and Teneligliptin 20 mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release, increase insulin secretion, and decrease gastric emptying, contributing to improved postprandial and fasting blood glucose levels. The extended-release formulation ensures gradual drug release, minimizing gastrointestinal side effects commonly associated with Metformin immediate-release formulations and improving patient compliance. Gliptinaid M 1000 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with Metformin is insufficient. It should be used with caution in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Regular monitoring of blood glucose, renal function, and potential adverse effects such as lactic acidosis is recommended. This combination therapy offers a complementary mechanism of action, optimizing glycemic management while reducing the risk of hypoglycemia.